TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29058816

Group type: EXPERIMENTAL
Intervention: Oral bosutinib (100 mg × 5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous bosutinib (120 mg in approximately 240 mL over 1 hour)
Number of subjects: 14
Study: 29059387

Group type: EXPERIMENTAL
Intervention: Parental perceptions of tobacco smoke exposure
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Parental misconceptions about tobacco smoke exposure
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Parental awareness of child exposure to tobacco smoke
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sensory perceptions used by parents
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Scientific information provided to parents
Number of subjects: 65
Study: 29059466

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: C-reactive protein values and increase of >10% in liver stiffness after TIPS
Number of subjects: 83

Group type: COMPARATOR
Intervention: Shear wave elastography of liver and spleen
Number of subjects: 83
Study: 29060496

Group type: EXPERIMENTAL
Intervention: New FoG-detection method using temporal, spatial, and physiological features with a support-vector-machine classifier.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Energy-based detection method.
Number of subjects: 0
Study: 29061603

Group type: EXPERIMENTAL
Intervention: Online tool for improving access to financial benefits
Number of subjects: 0
Study: 29061725

Group type: EXPERIMENTAL
Intervention: Central ambulatory systolic pressure measured with a validated oscillometric device
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Brachial ambulatory systolic pressure
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Brachial office blood pressure
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Left ventricular mass determined by echocardiography
Number of subjects: 289
Study: 29062240

Group type: EXPERIMENTAL
Intervention: Oliceridine regimen A (1.5/0.10 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oliceridine regimen B (1.5/0.35 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Morphine (4.0/1.0 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 29062524

Group type: EXPERIMENTAL
Intervention: Decision guide for elderly care decision-making
Number of subjects: 0
Study: 29063494

Group type: EXPERIMENTAL
Intervention: Transcatheter left gastric artery embolization (LGAE)
Number of subjects: 5
Study: 29063805

Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Short telomeres
Number of subjects: 110
Study: 29063814

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD; Epidiolex; Greenwich Biosciences)
Number of subjects: 3
Study: 29064263

Group type: EXPERIMENTAL
Intervention: Delirium (diagnosed using confusion assessment method)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Delirium (prevalent and incident)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Delirium (overall and prevalent)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Delirium (overall, incident, or prevalent)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Positive confusion assessment method
Number of subjects: 726
Study: 29064349

Group type: EXPERIMENTAL
Intervention: Bosentan monotherapy for 16 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Add-on sildenafil for an additional 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: cMRI-derived parameters
Number of subjects: 100
Study: 29064772

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 38
Study: 29064927

Group type: EXPERIMENTAL
Intervention: Rectal distension stimulations in patients with IBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectal distension stimulations in healthy controls
Number of subjects: 0
Study: 29065747

Group type: EXPERIMENTAL
Intervention: Total marrow irradiation (TMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous melphalan
Number of subjects: 0
Study: 29065865

Group type: EXPERIMENTAL
Intervention: Exenatide 5 to 10 μg twice a day for 20 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 71
Study: 29065892

Group type: EXPERIMENTAL
Intervention: Eotaxin
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: IL-2, IL-6, IL-8, eotaxin
Number of subjects: 3239

Group type: EXPERIMENTAL
Intervention: CCL17
Number of subjects: 3239
Study: 29065923

Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) treatment for 6 months
Number of subjects: 50
Study: 29065931

Group type: EXPERIMENTAL
Intervention: Radiographic sacroiliitis (measured by sacroiliitis sum score between 0 and 8)
Number of subjects: 210
Study: 29065955

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0
Study: 29065956

Group type: EXPERIMENTAL
Intervention: Negative hyperpnea pattern
Number of subjects: 33

Group type: COMPARATOR
Intervention: Positive hyperpnea pattern
Number of subjects: 33
Study: 29066389

Group type: EXPERIMENTAL
Intervention: TLC-PD15 (total lung capacity-adjusted lung density)
Number of subjects: 3390

Group type: EXPERIMENTAL
Intervention: Decline in TLC-PD15
Number of subjects: 3390
Study: 29066505

Group type: EXPERIMENTAL
Intervention: Pan-AKT Inhibitor AZD5363
Number of subjects: 0
Study: 29066590

Group type: EXPERIMENTAL
Intervention: Home Pulmonary Rehabilitation (PR) program including a computer tablet, activity monitor, and oximeter, with 12 min of walking and 6 full-body exercises, completed 6 days/week, plus weekly telephone calls with the PR health coach.
Number of subjects: 0
Study: 29067298

Group type: EXPERIMENTAL
Intervention: Bexarotene (oral administration for 3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (oral administration for 3 days)
Number of subjects: 9
Study: 29067304

Group type: EXPERIMENTAL
Intervention: Aducanumab (0.3, 1, 3, 10, 20, 30, and 60 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29067328

Group type: EXPERIMENTAL
Intervention: Unstructured conversations with standardized preselected topics
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Linguistic features obtained by LIWC
Number of subjects: 41
Study: 29067332

Group type: EXPERIMENTAL
Intervention: UB-311 (synthetic peptide vaccine)
Number of subjects: 0
Study: 29067347

Group type: EXPERIMENTAL
Intervention: Best practices hearing intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Successful aging intervention
Number of subjects: 40
Study: 29067643

Group type: EXPERIMENTAL
Intervention: Gedatolisib (PF-05212384) with Irinotecan 180 mg/m
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF-04691502
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gedatolisib (PF-05212384) with PD-0325901
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF-04691502 with PD-0325901
Number of subjects: 0
Study: 29067842

Group type: EXPERIMENTAL
Intervention: Shared reading
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 282
Study: 29068794

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day) as monotherapy or adjunctive therapy
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (higher than recommended doses)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Quetiapine XR as adjunctive therapy to antidepressants
Number of subjects: 811
Study: 29069114

Group type: EXPERIMENTAL
Intervention: Concomitant calcium channel blocker (CCB) plus antipsychotic (AP) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antipsychotic (AP) therapy alone
Number of subjects: 0
Study: 29070010

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice-daily for 1 year
Number of subjects: 72
Study: 29070480

Group type: EXPERIMENTAL
Intervention: Internet-delivered dialectical behavior therapy (DBT) skills training, 8-week intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study: 29070555

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29070559

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study: 29070638

Group type: EXPERIMENTAL
Intervention: Heterosexually identified MSM
Number of subjects: 600
Study: 29070641

Group type: EXPERIMENTAL
Intervention: Dementia Population Risk Tool (DemPoRT)
Number of subjects: 44052
Study: 29070939

Group type: EXPERIMENTAL
Intervention: palucorcel (CNTO 2476) administered subretinally at a targeted dose of 3.0×10
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: palucorcel (CNTO 2476)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: alternative subretinal delivery methods for palucorcel
Number of subjects: 7
Study: 29071072

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT) during exercise tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control) during exercise tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT)
Number of subjects: 0
Study: 29071077

Group type: EXPERIMENTAL
Intervention: BreatheSmart mobile technology (wireless Bluetooth-enabled inhaler sensors and mSpirometer)
Number of subjects: 100
Study: 29071087

Group type: EXPERIMENTAL
Intervention: DS-8500a 10 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 29071091

Group type: EXPERIMENTAL
Intervention: RenalGuard system with weight-adjusted intravenous furosemide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RenalGuard system
Number of subjects: 10
Study: 29071264

Group type: EXPERIMENTAL
Intervention: High ligation of the IMA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low ligation of the IMA
Number of subjects: 100
Study: 29071307

Group type: EXPERIMENTAL
Intervention: Original, intensive STOMP protocol (3 hours/day, 5 days/week for 2 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Less-intensive STOMP protocol (1 hour/day, 2 days/week for 2 weeks)
Number of subjects: 32
Study: 29071793

Group type: EXPERIMENTAL
Intervention: High-fat diet (140% caloric intake, 44% from fat) for 8 weeks
Number of subjects: 29
Study: 29071802

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise + Weight Loss (AEX + WL)
Number of subjects: 65
Study: 29072473

Group type: EXPERIMENTAL
Intervention: Total PTS symptoms
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Intrusion symptoms
Number of subjects: 697
Study: 29072772

Group type: EXPERIMENTAL
Intervention: Bosutinib treatment in CP2L cohort
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Bosutinib treatment in CP3L cohort
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Patients with chronic diarrhea in CP2L cohort
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Patients with chronic diarrhea in CP3L cohort
Number of subjects: 403
Study: 29072975

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
Number of subjects: 16
Study: 29073343

Group type: EXPERIMENTAL
Intervention: LUTS (self-reported)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Storage category of LUTS
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Voiding category of LUTS
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Post-micturition category of LUTS
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Higher than median HAQ DI in storage category
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Higher than median HAQ DI for digestive symptoms burden in voiding category
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Synovitis in voiding category
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Digestive symptoms burden in post-micturition category
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL)
Number of subjects: 334
Study: 29073362

Group type: EXPERIMENTAL
Intervention: Early implant placement with simultaneous contour augmentation through guided bone regeneration with a 2-layer composite graft
Number of subjects: 20
Study: 29073584

Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg/d
Number of subjects: 1215
Study: 29074030

Group type: EXPERIMENTAL
Intervention: Xpert CT/NG Assay (Cepheid, Sunnyvale, CA) using a urine sample
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Aptima Combo 2 Assay (Gen-Probe Incorporated, San Diego, CA) using a swab sample
Number of subjects: 1162
Study: 29074183

Group type: EXPERIMENTAL
Intervention: BD Onclarity HPV assay
Number of subjects: 276

Group type: COMPARATOR
Intervention: HC2
Number of subjects: 276

Group type: COMPARATOR
Intervention: Onclarity
Number of subjects: 276

Group type: COMPARATOR
Intervention: LA
Number of subjects: 276
Study: 29074187

Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 10706

Group type: EXPERIMENTAL
Intervention: Non-vaccine HPV types (35/39/51/56/59)
Number of subjects: 10706

Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 10706
Study: 29074501

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d until progression or intolerance
Number of subjects: 40
Study: 29074512

Group type: EXPERIMENTAL
Intervention: Tidal breathing parameters measured at term-equivalent age in EP-born infants
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tidal breathing parameters
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy term-born infants (control group)
Number of subjects: 52
Study: 29074518

Group type: EXPERIMENTAL
Intervention: Bimodal neuromodulation device with three different stimulation parameter sets for 12 weeks
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Bimodal neuromodulation device
Number of subjects: 342
Study: 29074543

Group type: EXPERIMENTAL
Intervention: Occupational exposure to carcinogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 29075620

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs), specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 29075855

Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) monotherapy at 1.25 mg/kg intravenously every 2 weeks
Number of subjects: 66
Study: 29076110

Group type: EXPERIMENTAL
Intervention: Upadacitinib (1-48 mg immediate-release doses)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Upadacitinib (in RA patients)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Upadacitinib (in RA patients with renal impairment)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Upadacitinib (compared to healthy volunteers)
Number of subjects: 572
Study: 29077645

Group type: EXPERIMENTAL
Intervention: Diet Rite Cola, sweetened with 68-mg sucralose and 41-mg ace-K
Number of subjects: 34
Study: 29077711

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (4,000 IU/d for VDAART and 2,400 IU/d for COPSAC2010)
Number of subjects: 1387
Study: 29077855

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training) - 12 weeks, 3 days per week of 4 × 4 minute intervals at over 90% of peak aerobic capacity (VO2peak) with 2 days per week of treadmill walking at 70% VO2peak.
Number of subjects: 27

Group type: COMPARATOR
Intervention: SED (Sedentary Control) - 12 weeks, no exercise intervention.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training) - 12 weeks.
Number of subjects: 27

Group type: COMPARATOR
Intervention: SED (Sedentary Control) - 12 weeks.
Number of subjects: 27
Study: 29077908

Group type: EXPERIMENTAL
Intervention: LIN28B (rs7759938)
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: FSHB c.-211G>T (rs10835638) and FSHR c.-29G>A (rs1394205) minor allele count
Number of subjects: 1478
Study: 29077941

Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) 0.5-1.5 mg/kg in combination with temozolomide (arm B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) 1.25 mg/kg as monotherapy (arm C)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Depatuxizumab mafodotin (depatux-m)
Number of subjects: 38
Study: 29077963

Group type: EXPERIMENTAL
Intervention: Movement System Impairment-Based Classification Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Exercises
Number of subjects: 0
Study: 29078170

Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 570

Group type: COMPARATOR
Intervention: Non-Type D personality
Number of subjects: 570
Study: 29078273

Group type: EXPERIMENTAL
Intervention: Bevacizumab (anti-VEGF drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking EPO function (pharmacological approach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic loss-of-function (deletion of EpoR in nonerythroid cells)
Number of subjects: 0
Study: 29078755

Group type: EXPERIMENTAL
Intervention: NPI-NH
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CSDD
Number of subjects: 83

Group type: COMPARATOR
Intervention: Actigraphy
Number of subjects: 83
Study: 29078773

Group type: EXPERIMENTAL
Intervention: Anti-malarial treatment
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: Bed net use
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: Microscopy assessment of PfPR
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: PfPR over 3 years
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: PfPR by age group
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: Fever and anaemia
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: Local PfPR variation
Number of subjects: 6401

Group type: EXPERIMENTAL
Intervention: Children 6 months-4 years
Number of subjects: 6401
Study: 29079275

Group type: EXPERIMENTAL
Intervention: Women with endometriosis (WwE)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control women (CW)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Subfertile WwE
Number of subjects: 268

Group type: COMPARATOR
Intervention: Subfertile CW
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Fertile WwE
Number of subjects: 268

Group type: COMPARATOR
Intervention: Fertile CW
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: WwE with rASRM I/II
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: WwE with rASRM III/IV
Number of subjects: 268

Group type: COMPARATOR
Intervention: CW
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: WwE with superficial peritoneal endometriosis
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: WwE with ovarian endometriosis
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: WwE with deep infiltrating endometriosis
Number of subjects: 268
Study: 29079496

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Renal mass biopsy (RMB)
Number of subjects: 95
Study: 29079551

Group type: EXPERIMENTAL
Intervention: Prehabilitation (tailored physical training for 3-6 weeks before surgery)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (standard ERAS pathway without prehabilitation)
Number of subjects: 56
Study: 29079600

Group type: EXPERIMENTAL
Intervention: Anagrelide (Xagrid)
Number of subjects: 3649

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3649
Study: 29079633

Group type: EXPERIMENTAL
Intervention: Severe persistent hyponatraemia (serum sodium <130 mmol/L)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (without severe persistent hyponatraemia)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: RV dysfunction
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hyponatraemia
Number of subjects: 116
Study: 29079658

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurements using Abbott assay, sex-specific 99th percentiles (women, 16 ng/L; men, 34 ng/L)
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) measurements
Number of subjects: 1555
Study: 29079987

Group type: EXPERIMENTAL
Intervention: Novel DGP treatment (specifics not provided)
Number of subjects: 90
Study: 29080061

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CTh+)
Number of subjects: 362

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 362

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: CTh+
Number of subjects: 362
Study: 29080065

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT) for 5 weeks
Number of subjects: 9
Study: 29080864

Group type: EXPERIMENTAL
Intervention: Transradial cardiac catheterization
Number of subjects: 50
Study: 29080915

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 25

Group type: COMPARATOR
Intervention: 8 mg triamcinolone
Number of subjects: 25
Study: 29080970

Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibrutinib 1680 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 20
Study: 29081368

Group type: EXPERIMENTAL
Intervention: JE-CV (single dose)
Number of subjects: 250
Study: 29081664

Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/day
Number of subjects: 302

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study: 29081977

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Control (no statin therapy)
Number of subjects: 3234
Study: 29082335

Group type: EXPERIMENTAL
Intervention: Daily 12-lead ECG once daily for 5 days
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 24-h Holter monitoring
Number of subjects: 1200
Study: 29082650

Group type: EXPERIMENTAL
Intervention: Telbivudine therapy throughout pregnancy
Number of subjects: 0
Study: 29082856

Group type: EXPERIMENTAL
Intervention: H. pylori infection in T2DM patients
Number of subjects: 797

Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 797
Study: 29083031

Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Training (IBT)
Number of subjects: 0